https://biotechmorning.com/news/penicillin-recall-syphilis-crisis Biotech Morning en 2026-07-08T14:25:33.912Z America's Only Syphilis Drug for Pregnant Women Just Vanished From Shelves https://biotechmorning.com/news/astrazeneca-amyloidosis-drug-phase-3-failure Biotech Morning en 2026-07-08T14:24:46.049Z AstraZeneca's Amyloidosis Drug Just Flopped. But There's a Plot Twist. https://biotechmorning.com/news/novo-nordisk-hims-wegovy-ozempic-telehealth-deal Biotech Morning en 2026-07-08T14:23:56.300Z From Lawsuit to Love Story: How Novo Nordisk and Hims Buried the Hatchet https://biotechmorning.com/news/intellia-crispr-trial-pause-safety-concern Biotech Morning en 2026-07-08T14:22:59.999Z Intellia's CRISPR Dream Just Hit a Wall https://biotechmorning.com/news/ionis-tryngolza-expanded-approval-blockbuster Biotech Morning en 2026-07-08T14:22:07.998Z Ionis Just Turned a Rare Disease Drug Into a $3 Billion Opportunity https://biotechmorning.com/news/fda-cder-staff-exodus-drug-approvals-at-risk Biotech Morning en 2026-07-08T14:21:15.515Z The FDA Is Running Out of People Who Know How to Approve Your Drugs https://biotechmorning.com/news/kailera-oral-obesity-pill-phase-3-china Biotech Morning en 2026-07-08T14:20:19.736Z The Obesity Pill That Could Crash Big Pharma's Party https://biotechmorning.com/news/lilly-ajax-2-3b-jak2-inhibitor-deal Biotech Morning en 2026-07-08T14:19:27.242Z Lilly Just Paid $2.3B for a Phase 1 Drug. Here's the Bet. https://biotechmorning.com/news/vera-therapeutics-atacicept-trutakna-iga-nephropathy-fda-approval Biotech Morning en 2026-07-08T14:18:36.440Z A Kidney Disease With No Good Options Just Got Its Sixth FDA-Approved Drug https://biotechmorning.com/news/intrabio-first-drug-ataxia-telangiectasia Biotech Morning en 2026-07-07T14:29:57.932Z The First Drug That Could Actually Treat This Childhood Disease Nobody Talks About https://biotechmorning.com/news/doctors-sue-cdc-childhood-vaccine-schedule Biotech Morning en 2026-07-07T14:29:07.632Z Doctors Just Took the CDC to Court Over Your Kid's Vaccine Schedule https://biotechmorning.com/news/sarepta-black-box-warning-layoffs-duchenne Biotech Morning en 2026-07-07T14:28:13.988Z Sarepta's Worst Week: A Black Box, 500 Pink Slips, and No Easy Answers https://biotechmorning.com/news/gilead-tubulis-5-billion-adc-acquisition-3 Biotech Morning en 2026-07-07T14:27:20.072Z Gilead Just Paid $5 Billion for a Company That Raised €10.7M Six Years Ago https://biotechmorning.com/news/vertex-10-billion-crinetics-endocrinology-deal Biotech Morning en 2026-07-07T14:26:27.207Z Vertex Just Bet $10 Billion on a Body Part Nobody Talks About https://biotechmorning.com/news/jnj-shrugs-off-mfn-drug-pricing Biotech Morning en 2026-07-07T14:25:28.261Z J&J Just Shrugged Off the Government's Drug Pricing Hammer https://biotechmorning.com/news/genentech-layoffs-breast-cancer-deal Biotech Morning en 2026-07-07T14:24:29.707Z Genentech Cut 103 Jobs and Wrote a $490M Check on the Same Day https://biotechmorning.com/news/scribe-therapeutics-ipo-gene-editing-cholesterol Biotech Morning en 2026-07-07T14:23:33.495Z The Gene Editing Company That Wants to Replace Your Cholesterol Meds https://biotechmorning.com/news/novartis-myricx-bio-adc-acquisition Biotech Morning en 2026-07-07T14:22:37.298Z Novartis Just Dropped $1.1B on a Company With Zero Clinical Data